Comments on the new European society of cardiology guidelines (2011) for the management of dyslipidaemias;Kommentar zu den neuen leitlinien (2011) der Europäischen gesellschaft für kardiologie zum management von dyslipidämien

Kardiologe

Volumn 6, Issue 3, 2012, Pages 210-216

  Koenig, W ^a   Marx, N ^b   Thiery, J ^c   Klose, G ^d  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d Internistische Gemeinschaftspraxis Beckenbauer/Maierhof Bremen   (Germany)

Author keywords

Consensus quality; Evidence quality; Global risk; Risk guided therapy; Therapeutic goals

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT INDICATION;

EID: 84863610320     PISSN: 18649718     EISSN: 18649726     Source Type: Journal    
DOI: 10.1007/s12181-012-0420-0     Document Type: Article

References (24)

1. Reiner Z, Catapano AL, De Backer G et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32:1769-1818
2. Catapano AL, Reiner Z, De Backer G et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217(Suppl 1):1-44
3. Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur J Cardiovasc Prev Rehabil 14(Suppl 2):E1-E40
4. Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375-2414
5. Mathes P, Thiery J (2005) Die Rolles des Lipidstoffwechsels in der Prävention der koronaren Herzerkrankung. Z Kardiol 94(Suppl 3):III/43-III/55
6. Grundy SM, Cleeman JI, BaireyMerz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110:227-239 (Pubitemid 38924592)
7. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensiveversus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504 (Pubitemid 38477774)
8. Cholesterol Treatment Trialists' (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376:1670-1681
9. Pedersen TR, Faergeman O, Kastelein JJ et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 294:2437-2445 (Pubitemid 41627921)
10. La Rosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435 (Pubitemid 40471450)
11. Haffner SM, Lehto S, Rönnemaa T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234 (Pubitemid 28350165)
12. Wannamathee SG, Shaper AG, Whincup PH et al (2011) Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men. Influence of age at onset, diabetes duration, and established and novel riskfactors. Arch Intern Med 171:404-410
13. Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377:2181-2192
14. FDA (2010) FDA Drug Safety Communication: ongoing safety review of high-dose zocor (simvastatin) and increased risk of muscle injury. 19. März 2010. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand-Providers/default.htm
15. Gitt AK, Juenger C, Jannowitz C et al (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high riskfor cardiovascular events by cardiologists in clinical practice: the 2 L cardio registry. Eur J Cardiovasc Prev Rehabil 16:438-444
16. Klose K, Schwabe U (2011) Lipidsenkende Mittel. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport. Springer, Berlin Heidelberg New York
17. Marchant I, Boissel JP, Kassai B et al (2009) SCORE should be preferred to Framingham to predict cardiovascular death in French population. Eur J Cardiovasc Prev Rehabil 16:609-615
18. Ajani UA, Ford ES (2006) Has the riskfor coronary heart disease changed among U. S. adults? J Am Coll Cardiol 48:1177-1182 (Pubitemid 44345144)
19. Ridker PM, Macfadyen JG, Nordestgaard BG et al (2010) Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5-10% and 10-20% 10-year risk. Implications of the justification for use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes 3:447-452
20. Smith SC, Benjamin EJ, Bonow RO et al (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease, 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458-2473
21. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634-1639
22. AIM-HIGH Investigators, Boden WE, Anderson T et al (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267
23. Versmissen J, Oosterveer DM, Yazdanpanah M et al (2008) Efficacy of statins in familial hypercholesterolemia: a long term cohort study. BMJ 11:337:a2423
24. Neugebauer E (2007) Leitlinienqualität = Evidenzqualität plus Konsensqualität? Z Arztl Fortbild QualGesundhWes (ZaeFQ) 101:83-84